FWB:MOR

MorphoSys AG Reports First Quarter 2024 Financial Results

Retrieved on: 
Monday, April 29, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Sale, FDA, Bone marrow, BET, Research and development, EDT, Investment, Safety, JAK, Food, EZH1, Research, Marketing, EZH2, Administration, ASCO, Novartis, Ruxolitinib, Patient, Supervisory board, Society, Acquisition, Operating cost, Annual general meeting, G&A, European Medicines Agency

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.
  • The financial results presented for the first quarter of 2024 relate to continuing business operations of MorphoSys.
  • Full Year 2024 Financial Guidance:
    As a consequence of the sale and transfer of tafasitamab to Incyte on February 5, 2024, MorphoSys' 2024 financial guidance published on January 30, 2024, cannot be maintained and therefore was revoked.
  • MorphoSys Group Key Figures (IFRS, end of the first quarter: March 31, 2024)

MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

Retrieved on: 
Thursday, April 11, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Cancer, EDT, MorphoSys, Takeover, ADS, Novartis, Patient, Supervisory board, Acquisition

The Management Board and Supervisory Board of MorphoSys AG (FSE: MOR; NASDAQ: MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as “Novartis”), recommending that shareholders accept the offer and tender their MorphoSys shares.

Key Points: 
  • The Management Board and Supervisory Board of MorphoSys AG (FSE: MOR; NASDAQ: MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as “Novartis”), recommending that shareholders accept the offer and tender their MorphoSys shares.
  • Novartis offers MorphoSys shareholders € 68.00 per share in cash, representing a total equity value of € 2.7 billion (the “Takeover Offer”).
  • “The offer made by Novartis provides MorphoSys shareholders with an opportunity to realize significant value upfront and with certainty.
  • The MorphoSys Management Board and Supervisory Board joint reasoned statement, as well as other relevant information for shareholders, is available on the MorphoSys website at https://www.morphosys.com/en/investors/Novartis-TakeoverOffer .

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 13, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Tafasitamab, Novartis, Operating cost, Sale, G&A, Asset, Trial of the century, Marketing, European Medicines Agency, Ruxolitinib, Investment, FDA, Food, Cryptocurrency

Cost of Sales: For the full year 2023, cost of sales were € 58.4 million compared to € 48.6 million in 2022.

Key Points: 
  • Cost of Sales: For the full year 2023, cost of sales were € 58.4 million compared to € 48.6 million in 2022.
  • R&D Expenses: For the full year 2023, R&D expenses were € 283.6 million compared to € 297.8 million in 2022.
  • SG&A Expenses: Selling expenses for the full year 2023 were € 81.4 million compared to € 92.4 million in 2022.
  • MorphoSys Group Key Figures (IFRS, end of financial year: December 31, 2023)

MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

Retrieved on: 
Monday, December 11, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cough, FACP, Spleen, PST, Food, European Medicines Agency, JAK, GMT, ASH, Headache, Plasma, Disease, Constipation, IL-6, Fatigue, MorphoSys, Patient, Thrombocytopenia, CET, Periodic breathing, Weakness, COVID-19, Prognosis, Diarrhea, Nausea, Survival, EST, Dysgeusia, TNF, Anemia, Fibrosis, Ruxolitinib, BET, Bone marrow, Dizziness, Vaccine, Dietary supplement, Medical imaging

Average hemoglobin levels were greater in patients receiving pelabresib and ruxolitinib than in those receiving placebo plus ruxolitinib, starting at week 9 and continuing to week 24.

Key Points: 
  • Average hemoglobin levels were greater in patients receiving pelabresib and ruxolitinib than in those receiving placebo plus ruxolitinib, starting at week 9 and continuing to week 24.
  • Increased cytokine levels are associated with all four disease hallmarks; increased IL-8 levels are also associated with worse survival outcomes.
  • Discontinuation rates due to adverse events were 10.7% with pelabresib and ruxolitinib and 6.5% with placebo plus ruxolitinib.
  • “The four hallmarks of myelofibrosis – enlarged spleen, anemia, bone marrow fibrosis and disease-associated symptoms – have a strong impact on a patient’s life.

MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

Retrieved on: 
Monday, November 20, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, FSE, Ruxolitinib, MorphoSys, Patient, TSS, BET, JAK, Pharmaceutical industry, Medical imaging

MANIFEST-2 met its primary endpoint, as the combination therapy demonstrated a statistically significant and clinically meaningful improvement in the proportion of patients achieving at least a 35% reduction in spleen volume (SVR35) at week 24.

Key Points: 
  • MANIFEST-2 met its primary endpoint, as the combination therapy demonstrated a statistically significant and clinically meaningful improvement in the proportion of patients achieving at least a 35% reduction in spleen volume (SVR35) at week 24.
  • The key secondary endpoints assessing symptom improvement – proportion of patients achieving at least a 50% reduction in total symptom score (TSS50) and absolute change in total symptom score (TSS) from baseline at week 24 – showed a strong positive trend favoring the pelabresib and ruxolitinib combination.
  • “Importantly, we saw significant symptom improvements for the vast majority of patients in the study.
  • “The pelabresib and ruxolitinib combination therapy significantly reduced spleen volume – the best prognostic indicator we have at our disposal for long-term myelofibrosis patient outcomes.

MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 15, 2023
Biotechnology, Pharmaceutical, Health, Oncology, FSE, EZH1, Annual general meeting, PST, Food, JAK, ASH, Patient, ARID1A, FDA, Abstract, EST, Society, Ruxolitinib, EZH2, Fast Track, BET, Pharmaceutical industry, Video game, Tafasitamab, MorphoSys

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023.
  • “Sales of Monjuvi remain on track for its approved indication, allowing us to narrow our full-year 2023 guidance target.
  • Minjuvi royalty revenue of € 1.2 million for sales outside of the U.S. in the third quarter 2023 and € 4.1 million for the first nine months of 2023.
  • Events After the End of the Third Quarter of 2023:
    MorphoSys updated its financial guidance for 2023 financial year on October 25, 2023.

MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Operating cost, Ruxolitinib, SG, Tafasitamab, DLBCL, G&A, Patient, Administration, Research and development, R, Asset, Indolent lymphoma, Fine chemical, Cryptocurrency, Assurance services, Bookkeeping, Music, MorphoSys, Incyte

In addition, the first quarter of 2023 included a one-time effect from severance payments related to the restructuring of the research department.

Key Points: 
  • In addition, the first quarter of 2023 included a one-time effect from severance payments related to the restructuring of the research department.
  • Full Year 2023 Financial Guidance:
    100% of Monjuvi U.S. net product sales are recorded on MorphoSys’ income statement and related profit/loss is split 50/50 between MorphoSys and Incyte.
  • Additional information related to 2023 Financial Guidance:
    Tremfya® royalties will continue to be recorded as revenue without any cost of sales in MorphoSys’ income statement.
  • MorphoSys Group Key Figures (IFRS, end of the second quarter: June 30, 2023)

MorphoSys AG Reports First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Workforce, Rituximab, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, Ruxolitinib, Vincristine, AACR, MorphoSys, Doctor of Philosophy, Significant event audit, JAK, DLBCL, Lenalidomide, American Association for Cancer Research, Cyclophosphamide, FSE, Incyte, Sale, ASCO, BET, Prednisone, American Society of Clinical Oncology, Patient, Doxorubicin, Annual general meeting, Society, Safety, Beauty salon, Nursing, Video game, Pharmaceutical industry, Tafasitamab

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2023.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2023.
  • Minjuvi royalty revenue of € 0.7 million for sales outside of the U.S. in the first quarter 2023 (Q1 2022: € 0.7 million).
  • On March 14, 2023, MorphoSys announced that Lucinda Crabtree, Ph.D., will join the company as its Chief Financial Officer and member of the Management Board in the third quarter of 2023 at the latest.
  • Total revenues for the first quarter 2023 were € 62.3 million compared to € 41.5 million for the same period in 2022.

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

Retrieved on: 
Sunday, April 16, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, AACR, MorphoSys, Diarrhea, Progression-free survival, NR, DLBCL, Plot, Aes, Lenalidomide, Joint Planning and Development Office, American Association for Cancer Research, FSE, Multimedia, Immunotherapy, Teaching hospital, Incidence, ASCT, Patient, CR, Oncology, Abstract, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Thrombocytopenia, Polyclinic, ORR, Food, PR, Disease, Pharmaceutical industry, Nursing, Tafasitamab, Neutropenia

A partial response (PR) was observed in 16.2% of patients (95% CI = 8.9, 26.2; n =13).

Key Points: 
  • A partial response (PR) was observed in 16.2% of patients (95% CI = 8.9, 26.2; n =13).
  • Additional results include:
    Median duration of response was not reached after a median follow up of 44.0 months (95% CI = 29.9, 57.0).
  • Monjuvi, in combination with lenalidomide, was granted accelerated approval based on the one-year primary analysis of the L-MIND study.
  • The data for the five-year analysis of the L-MIND study have not yet been submitted to, or reviewed by, the FDA.

MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 15, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Constellation, Progression-free survival, Cancer, FSE, Workforce, Lenalidomide, DLBCL, Significant event audit, Lymphoma, Saskatchewan River Sturgeon Management Board, Tafasitamab, Patient, ASH, JAK, Safety, Doctor of Philosophy, Video game, Pharmaceutical industry, Ruxolitinib, Novartis, MorphoSys

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.
  • MorphoSys presented at ASH 2022 results from analyses of the ongoing MANIFEST study in patients with myelofibrosis.
  • Total revenues for the fourth quarter 2022 were € 81.6 million compared to € 52.9 million for the same period in 2021.
  • This increase resulted mainly from higher revenues from the global licensing agreement with Novartis executed in the fourth quarter 2022.